Manisha Koirala was diagnosed with stage IV ovarian cancer in 2012. She later made a recovery after undergoing treatment in ...

A cancer survivor is raising awareness about the importance of genetic testing. Why she believes it can be imperative to ...

In April 2025, the Company announced that the first patient had been dosed in Part 2a of the Phase 2 DENALI clinical trial ( NCT05128825) of azenosertib in patients with Cyclin E1+ platinum-resistant ...

In this video, Ursula A. Matulonis, MD, discusses new data on rinatabart sesutecan, or Rina-S, for patients with advanced ovarian cancer, which were presented at Society of Gynecologic Oncology Annual ...

In this video, Ursula A. Matulonis, MD, discusses results from the phase 3 MIRASOL trial of mirvetuximab soravtansine-gynx for patients with folate receptor alpha-positive, platinum-resistant ovarian ...

IMNN READ THE FULL IMNN RESEARCH REPORT Business Update First Site Activated for Phase 3 OVATION 3 Trial of IMNN-001 in ...

The U.S. Federal Drug Administration (FDA) has granted Incyclix Bio Fast Track designation for INX-315 to treat ...

ERNA-101 remains on track for IND-enabling studies in 2025, with first-in-human studies targeted for 2026.

In a recent clip, Dr Jackson-Spence shared a number of different symptoms that could actually be something more serious - ...

The addition of bevacizumab to first-line (1L) chemotherapy offers real-world benefit to patients with epithelial ovarian cancer with high-risk prognostic factors.

A Ludwig Cancer Research study has identified a key mechanism by which advanced ovarian cancers suppress anti-tumor immune responses and resist immunotherapies.